Previous 10 |
Halozyme Therapeutics (NASDAQ: HALO ): Q4 GAAP EPS of -$0.01 beats by $0.02 . Revenue of $60.2M (-68.2% Y/Y) beats by $0.45M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an upda...
AAOI , ACIA , ADSW , AL , AMH , ANIK , APPN , ATUS , BEAT , BIDU , BJRI , BMRN , BOOM , BYD , CATM , CBPX , CENX , CHSP , COLD , CUBE , CWST , CZR , DBX , DXCM , EBS , ECOL , ED , ENV , EVRG , EXAS , FIX , FLR , FSLR , GMED , HALO , HCC , HPE , HTGC , ...
Introduction - good things may be happening here I stopped trading or commenting on Alexion ( ALXN ) in the first half of 2017, when there were countless uncertainties. ALXN was around $110 and was sold at a small loss. ALXN closed Wednesday at $125.18, lagging the market ( SPY ) and a major...
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the fourth quarter 2018 on Thursday, February 21 at 4:30 p.m. E...
BREDA , the Netherlands and GHENT, Belgium and SAN DIEGO , Feb. 4, 2019 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's...
Quick Take Anchiano Therapeutics ( ANCN ) intends to raise $35 million in a U.S. IPO, per an amended regulatory filing . The company is developing a single biologic candidate to treat bladder and other cancers. ANCN has had promising trial results, strong existing investor support of th...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...